NCT06909604 Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
| NCT ID | NCT06909604 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Cancer Hospital & Institute |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-01-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥18 years old; ECOG 0 or 1; 2. Patients with HER2 positive or low tumors; 3. Receives neoadjuvant therapy 4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions; 5. Life expectancy \> 3 months - Exclusion Criteria: 1. Significant hepatic or renal dysfunction; 2. Is pregnant or ready to pregnant; 3. Cannot keep their states for half an hour; 4. Refused to join the clinical research; 5. Suffering from claustrophobia or other mental disorders; 6. Any other situation that researchers considered it unsuitable to participate in the trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06909604 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06909604 currently recruiting?
Yes, NCT06909604 is actively recruiting participants. Contact the research team at 15833916752@163.com for enrollment information.
Where is the NCT06909604 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06909604 clinical trial?
NCT06909604 is sponsored by Peking University Cancer Hospital & Institute. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.